• CD28 targeting
  • How it works

CD28 costimulation

PD-L1-dependent CD28 costimulation

 

Step 1 – Tumor-specific T cells recognize their target via their T cell receptor (TCR)

T cells continuously scan a body’s cells in search of abnormalities, e.g., cancer cells. T cells use their surface receptor, T cell receptor (TCR), to bind peptides from degraded cell proteins complexed to major histocompatibility complex (MHC) molecules at the cell surface on cells. If the T cell’s TCR locates an MHC/peptide complex on a cancer cell, the binding triggers the so-called T cell activation “signal 1” (represented by a star in the figure below), which is the first step toward T cell activation.

PD-L1-dependent CD28 Costimulation

Step 2 – Tumor cells express PD-L1 to suppress T cell attack

Tumor cells can escape T cell surveillance by expressing PD-L1 at their surface. PD-L1 plays a major role in suppressing T cell responses by engaging the inhibitory checkpoint receptor PD-1 expressed on T cells. PD-1 exerts its activity by dampening T cell activation signals, including signal 1. Consequently, tumor-specific T cells are often unable to proficiently kill the cancer cells.

PD-L1-dependent CD28 Costimulation 1

Step 3 – By blocking PD-L1, the inhibitory signal preventing T cell activation can be limited

Thanks to its blocking anti-PD-L1 arm, NI-3201 can prevent tumor-expressed PD-L1 from interacting with PD-1 expressed by T cells. In the absence of PD-1-derived inhibitory signal, T cells can be effectively activated, thereby restoring their anti-tumor activity.

PD-L1-dependent CD28 Costimulation

Step 4 – Delivery of T cell costimulation further enhance T cell activation and response, leading to cancer cell killing

However, complete T cell activation necessitates a secondary signal (signal 2), typically facilitated by the CD28 receptor. Activation of CD28 not only initiates full T cell activation but also promotes their survival. Upon interaction with PD-L1 on target cells, NI-3201 can induce CD28 agonism, thereby culminating in thorough T cell activation and effective elimination of targeted tumor cells.

PD-L1-dependent CD28 Costimulation 1

Interested by this approach for your own projects? Partner with us

All drawings have been created by BIORENDER

Back

Walter Ferlin will be speaking at Swiss Biotech Day 2026

Read more

LinkedIn